当前位置: X-MOL 学术J. Am. Acad. Child Adolesc. Psychiatry › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Systematic Review and Meta-Analysis: Effects of Pharmacological Treatment for Attention-Deficit/Hyperactivity Disorder on Quality of Life
Journal of the American Academy of Child and Adolescent Psychiatry ( IF 9.2 ) Pub Date : 2024-05-30 , DOI: 10.1016/j.jaac.2024.05.023
Alessio Bellato 1 , Nadia J Perrott 2 , Lucia Marzulli 3 , Valeria Parlatini 4 , David Coghill 5 , Samuele Cortese 6
Affiliation  

We conducted a systematic review and meta-analysis to quantify the effect of attention-deficit/hyperactivity disorder (ADHD) medication on quality of life (QoL), and to understand whether this effect differs between stimulants and non-stimulants. From the dataset of a published network meta-analysis (Cortese et al., 2018), updated on 27 February 2023 (), we identified randomized controlled trials (RCTs) of ADHD medications for individuals aged 6 years or more with a diagnosis of ADHD based on the (from third to fifth editions) or the ( ninth or tenth revision), reporting data on QoL (measured with a validated scale). The risk of bias for each RCTs was assessed using the Cochrane Risk of Bias tool 2. Multi-level meta-analytic models were conducted with R 4.3.1. We included 17 RCTs (5,388 participants in total; 56% randomized to active medication) in the meta-analyses. We found that amphetamines (Hedge's = 0.51, 95% CI = 0.08, 0.94), methylphenidate (0.38; 0.23, 0.54), and atomoxetine (0.30; 0.19, 0.40) were significantly more efficacious than placebo in improving QoL in people with ADHD, with moderate effect size. For atomoxetine, these effects were not moderated by the length of intervention, and did not differ between children/adolescents and adults. In addition to being efficacious in reducing ADHD core symptom severity, both stimulant and non-stimulant medications are efficacious in improving QoL in people with ADHD, albeit with lower effect sizes. Future research should explore whether, and to what degree, combining pharmacological and non-pharmacological interventions is likely to further improve QoL in people with ADHD. Effects of pharmacological treatment for ADHD on quality of life: a systematic review and meta-analysis; .

中文翻译:


系统评价和荟萃分析:药物治疗注意力缺陷/多动症对生活质量的影响



我们进行了系统回顾和荟萃分析,以量化注意力缺陷/多动症 (ADHD) 药物对生活质量 (QoL) 的影响,并了解兴奋剂和非兴奋剂之间的这种影响是否存在差异。根据 2023 年 2 月 27 日更新的已发表网络荟萃分析(Cortese 等人,2018)的数据集 (),我们确定了针对 6 岁或以上诊断为 ADHD 的个体的 ADHD 药物随机对照试验 (RCT)基于(第三版至第五版)或(第九版或第十版),报告生活质量数据(用经过验证的量表测量)。使用 Cochrane 偏倚风险工具 2 评估每个 RCT 的偏倚风险。使用 R 4.3.1 进行多级荟萃分析模型。我们在荟萃分析中纳入了 17 项随机对照试验(总共 5,388 名受试者;56% 的受试者随机接受积极药物治疗)。我们发现,安非他明(Hedge's = 0.51,95% CI = 0.08,0.94)、哌醋甲酯(0.38;0.23,0.54)和托莫西汀(0.30;0.19,0.40)在改善 ADHD 患者的生活质量方面明显比安慰剂更有效。效应大小适中。对于阿托莫西汀,这些影响不会因干预时间的长短而减弱,并且在儿童/青少年和成人之间没有差异。除了有效减轻 ADHD 核心症状的严重程度外,兴奋剂和非兴奋剂药物都可以有效改善 ADHD 患者的生活质量,尽管效果较小。未来的研究应该探讨药物和非药物干预措施的结合是否以及在多大程度上可能进一步改善多动症患者的生活质量。 ADHD 药物治疗对生活质量的影响:系统评价和荟萃分析; 。
更新日期:2024-05-30
down
wechat
bug